Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Chondrogen · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | Chondrogen (low dose) |
| B | EXPERIMENTAL | Chondrogen (high dose) |
| C | PLACEBO_COMPARATOR | Hyaluronan |
| Name | Type | Description |
|---|---|---|
| Chondrogen | DRUG | Intra-articular injection of ex vivo cultured adult human mesenchymal stem cells |
| Placebo | DRUG | Intra-articular injection of Hyaluronan |
Inclusion Criteria: * Subject must have received an injection in Protocol No. 550 * Subject must have completed the 6-month and final 2-year visit in Protocol No. 550 * Subject must provide written informed consent for entry into the extension study * Subject must provide authorization for use and ...
Chondrogen is an investigational small molecule being studied for recovery following partial medial meniscectomy, a surgical procedure on the knee. It is delivered by intra-articular injection directly into the joint. The drug is in Phase 1 clinical development and is not yet approved by the FDA.
Chondrogen is being developed by Mesoblast Limited, a biopharmaceutical company traded on the NASDAQ under the ticker symbol MESO. Mesoblast is conducting clinical trials to evaluate the safety and efficacy of Chondrogen for patients recovering from partial medial meniscectomy.
Chondrogen is currently in Phase 1 clinical development. It has completed one Phase 1 trial, which was a randomized, double-blind, placebo-controlled study. The drug is investigational and has not received FDA approval. Further clinical studies would be needed to assess its safety and effectiveness.
Chondrogen has been studied in one completed clinical trial, registered as NCT00702741. This Phase 1 study, titled 'Follow-up Study of Chondrogen® Delivered by Intra-Articular Injection Following Meniscectomy,' enrolled 55 participants in the United States. The trial was randomized, double-blind, and placebo-controlled, and it has been completed.
Chondrogen is administered by intra-articular injection, meaning it is injected directly into the knee joint. This route of administration is used in the clinical trial for patients recovering from partial medial meniscectomy. The drug is being evaluated as a potential treatment to aid in recovery following this surgical procedure.